Report Detail

Pharma & Healthcare Global Super Generic Drugs Market Outlook 2021

  • RnM4271964
  • |
  • 02 January, 2021
  • |
  • Global
  • |
  • 122 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Super Generic Drugs Market Overview

  • 1.1 Product Overview and Scope of Super Generic Drugs
  • 1.2 Super Generic Drugs Segment by Type
    • 1.2.1 Global Super Generic Drugs Sales Growth Rate Comparison by Type (2020-2026)
    • 1.2.2 Traditional Generic Drugs
    • 1.2.3 Biosimilars
  • 1.3 Super Generic Drugs Segment by Application
    • 1.3.1 Super Generic Drugs Sales Comparison by Application: (2020-2026)
    • 1.3.2 CNS
    • 1.3.3 Cardiovascular
    • 1.3.4 Genitourinary/Hormonal Drugs
    • 1.3.5 Respiratory
    • 1.3.6 Rheumatology
    • 1.3.7 Diabetes
    • 1.3.8 Oncology
    • 1.3.9 Others
  • 1.4 Global Super Generic Drugs Market Size Estimates and Forecasts
    • 1.4.1 Global Super Generic Drugs Revenue 2015-2026
    • 1.4.2 Global Super Generic Drugs Sales 2015-2026
    • 1.4.3 Super Generic Drugs Market Size by Region: 2020 Versus 2026

2 Global Super Generic Drugs Market Competition by Manufacturers

  • 2.1 Global Super Generic Drugs Sales Market Share by Manufacturers (2015-2020)
  • 2.2 Global Super Generic Drugs Revenue Share by Manufacturers (2015-2020)
  • 2.3 Global Super Generic Drugs Average Price by Manufacturers (2015-2020)
  • 2.4 Manufacturers Super Generic Drugs Manufacturing Sites, Area Served, Product Type
  • 2.5 Super Generic Drugs Market Competitive Situation and Trends
    • 2.5.1 Super Generic Drugs Market Concentration Rate
    • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
    • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 2.7 Primary Interviews with Key Super Generic Drugs Players (Opinion Leaders)

3 Super Generic Drugs Retrospective Market Scenario by Region

  • 3.1 Global Super Generic Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 3.2 Global Super Generic Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 3.3 North America Super Generic Drugs Market Facts & Figures by Country
    • 3.3.1 North America Super Generic Drugs Sales by Country
    • 3.3.2 North America Super Generic Drugs Sales by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Super Generic Drugs Market Facts & Figures by Country
    • 3.4.1 Europe Super Generic Drugs Sales by Country
    • 3.4.2 Europe Super Generic Drugs Sales by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Super Generic Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Super Generic Drugs Sales by Region
    • 3.5.2 Asia Pacific Super Generic Drugs Sales by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Super Generic Drugs Market Facts & Figures by Country
    • 3.6.1 Latin America Super Generic Drugs Sales by Country
    • 3.6.2 Latin America Super Generic Drugs Sales by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Super Generic Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Super Generic Drugs Sales by Country
    • 3.7.2 Middle East and Africa Super Generic Drugs Sales by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Super Generic Drugs Historic Market Analysis by Type

  • 4.1 Global Super Generic Drugs Sales Market Share by Type (2015-2020)
  • 4.2 Global Super Generic Drugs Revenue Market Share by Type (2015-2020)
  • 4.3 Global Super Generic Drugs Price Market Share by Type (2015-2020)
  • 4.4 Global Super Generic Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Super Generic Drugs Historic Market Analysis by Application

  • 5.1 Global Super Generic Drugs Sales Market Share by Application (2015-2020)
  • 5.2 Global Super Generic Drugs Revenue Market Share by Application (2015-2020)
  • 5.3 Global Super Generic Drugs Price by Application (2015-2020)

6 Company Profiles and Key Figures in Super Generic Drugs Business

  • 6.1 Teva
    • 6.1.1 Corporation Information
    • 6.1.2 Teva Description, Business Overview
    • 6.1.3 Teva Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.1.4 Teva Products Offered
    • 6.1.5 Teva Recent Development
  • 6.2 Novartis - Sandoz
    • 6.2.1 Novartis - Sandoz Corporation Information
    • 6.2.2 Novartis - Sandoz Description, Business Overview
    • 6.2.3 Novartis - Sandoz Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.2.4 Novartis - Sandoz Products Offered
    • 6.2.5 Novartis - Sandoz Recent Development
  • 6.3 Mylan
    • 6.3.1 Mylan Corporation Information
    • 6.3.2 Mylan Description, Business Overview
    • 6.3.3 Mylan Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.3.4 Mylan Products Offered
    • 6.3.5 Mylan Recent Development
  • 6.4 Sun Pharmaceutical
    • 6.4.1 Sun Pharmaceutical Corporation Information
    • 6.4.2 Sun Pharmaceutical Description, Business Overview
    • 6.4.3 Sun Pharmaceutical Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Sun Pharmaceutical Products Offered
    • 6.4.5 Sun Pharmaceutical Recent Development
  • 6.5 Aspen
    • 6.5.1 Aspen Corporation Information
    • 6.5.2 Aspen Description, Business Overview
    • 6.5.3 Aspen Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.5.4 Aspen Products Offered
    • 6.5.5 Aspen Recent Development
  • 6.6 Fresenius Kabi
    • 6.6.1 Fresenius Kabi Corporation Information
    • 6.6.2 Fresenius Kabi Description, Business Overview
    • 6.6.3 Fresenius Kabi Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.6.4 Fresenius Kabi Products Offered
    • 6.6.5 Fresenius Kabi Recent Development
  • 6.7 Pfizer (Hospira)
    • 6.6.1 Pfizer (Hospira) Corporation Information
    • 6.6.2 Pfizer (Hospira) Description, Business Overview
    • 6.6.3 Pfizer (Hospira) Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Pfizer (Hospira) Products Offered
    • 6.7.5 Pfizer (Hospira) Recent Development
  • 6.8 Sanofi
    • 6.8.1 Sanofi Corporation Information
    • 6.8.2 Sanofi Description, Business Overview
    • 6.8.3 Sanofi Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.8.4 Sanofi Products Offered
    • 6.8.5 Sanofi Recent Development
  • 6.9 Aurobindo
    • 6.9.1 Aurobindo Corporation Information
    • 6.9.2 Aurobindo Description, Business Overview
    • 6.9.3 Aurobindo Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.9.4 Aurobindo Products Offered
    • 6.9.5 Aurobindo Recent Development
  • 6.10 Lupin
    • 6.10.1 Lupin Corporation Information
    • 6.10.2 Lupin Description, Business Overview
    • 6.10.3 Lupin Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.10.4 Lupin Products Offered
    • 6.10.5 Lupin Recent Development
  • 6.11 Dr. Reddy's
    • 6.11.1 Dr. Reddy's Corporation Information
    • 6.11.2 Dr. Reddy's Super Generic Drugs Description, Business Overview
    • 6.11.3 Dr. Reddy's Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.11.4 Dr. Reddy's Products Offered
    • 6.11.5 Dr. Reddy's Recent Development
  • 6.12 Apotex
    • 6.12.1 Apotex Corporation Information
    • 6.12.2 Apotex Super Generic Drugs Description, Business Overview
    • 6.12.3 Apotex Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.12.4 Apotex Products Offered
    • 6.12.5 Apotex Recent Development
  • 6.13 Cipla
    • 6.13.1 Cipla Corporation Information
    • 6.13.2 Cipla Super Generic Drugs Description, Business Overview
    • 6.13.3 Cipla Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.13.4 Cipla Products Offered
    • 6.13.5 Cipla Recent Development
  • 6.14 ENDO (Par Pharmaceutical)
    • 6.14.1 ENDO (Par Pharmaceutical) Corporation Information
    • 6.14.2 ENDO (Par Pharmaceutical) Super Generic Drugs Description, Business Overview
    • 6.14.3 ENDO (Par Pharmaceutical) Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.14.4 ENDO (Par Pharmaceutical) Products Offered
    • 6.14.5 ENDO (Par Pharmaceutical) Recent Development
  • 6.15 Stada Arzneimittel
    • 6.15.1 Stada Arzneimittel Corporation Information
    • 6.15.2 Stada Arzneimittel Super Generic Drugs Description, Business Overview
    • 6.15.3 Stada Arzneimittel Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.15.4 Stada Arzneimittel Products Offered
    • 6.15.5 Stada Arzneimittel Recent Development
  • 6.16 Krka Group
    • 6.16.1 Krka Group Corporation Information
    • 6.16.2 Krka Group Super Generic Drugs Description, Business Overview
    • 6.16.3 Krka Group Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.16.4 Krka Group Products Offered
    • 6.16.5 Krka Group Recent Development
  • 6.17 Nichi-Iko Pharmaceutical
    • 6.17.1 Nichi-Iko Pharmaceutical Corporation Information
    • 6.17.2 Nichi-Iko Pharmaceutical Super Generic Drugs Description, Business Overview
    • 6.17.3 Nichi-Iko Pharmaceutical Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.17.4 Nichi-Iko Pharmaceutical Products Offered
    • 6.17.5 Nichi-Iko Pharmaceutical Recent Development
  • 6.18 Valeant
    • 6.18.1 Valeant Corporation Information
    • 6.18.2 Valeant Super Generic Drugs Description, Business Overview
    • 6.18.3 Valeant Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.18.4 Valeant Products Offered
    • 6.18.5 Valeant Recent Development
  • 6.19 Zydus Cadila
    • 6.19.1 Zydus Cadila Corporation Information
    • 6.19.2 Zydus Cadila Super Generic Drugs Description, Business Overview
    • 6.19.3 Zydus Cadila Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.19.4 Zydus Cadila Products Offered
    • 6.19.5 Zydus Cadila Recent Development
  • 6.20 Hikma
    • 6.20.1 Hikma Corporation Information
    • 6.20.2 Hikma Super Generic Drugs Description, Business Overview
    • 6.20.3 Hikma Super Generic Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 6.20.4 Hikma Products Offered
    • 6.20.5 Hikma Recent Development

7 Super Generic Drugs Manufacturing Cost Analysis

  • 7.1 Super Generic Drugs Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Raw Materials Price Trend
    • 7.1.3 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Super Generic Drugs
  • 7.4 Super Generic Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Super Generic Drugs Distributors List
  • 8.3 Super Generic Drugs Customers

9 Market Dynamics

  • 9.1 Market Trends
  • 9.2 Opportunities and Drivers
  • 9.3 Challenges
  • 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

  • 10.1 Global Super Generic Drugs Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Super Generic Drugs by Type (2021-2026)
    • 10.1.2 Global Forecasted Revenue of Super Generic Drugs by Type (2021-2026)
  • 10.2 Super Generic Drugs Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Super Generic Drugs by Application (2021-2026)
    • 10.2.2 Global Forecasted Revenue of Super Generic Drugs by Application (2021-2026)
  • 10.3 Super Generic Drugs Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Super Generic Drugs by Region (2021-2026)
    • 10.3.2 Global Forecasted Revenue of Super Generic Drugs by Region (2021-2026)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type, the Super Generic Drugs market is segmented into
    Traditional Generic Drugs
    Biosimilars

    Segment by Application
    CNS
    Cardiovascular
    Genitourinary/Hormonal Drugs
    Respiratory
    Rheumatology
    Diabetes
    Oncology
    Others

    Global Super Generic Drugs Market: Regional Analysis
    The Super Generic Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
    The key regions covered in the Super Generic Drugs market report are:
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    Global Super Generic Drugs Market: Competitive Analysis
    This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

    The major players in global Super Generic Drugs market include:
    Teva
    Novartis - Sandoz
    Mylan
    Sun Pharmaceutical
    Aspen
    Fresenius Kabi
    Pfizer (Hospira)
    Sanofi
    Aurobindo
    Lupin
    Dr. Reddy's
    Apotex
    Cipla
    ENDO (Par Pharmaceutical)
    Stada Arzneimittel
    Krka Group
    Nichi-Iko Pharmaceutical
    Valeant
    Zydus Cadila
    Hikma


    Summary:
    Get latest Market Research Reports on Super Generic Drugs. Industry analysis & Market Report on Super Generic Drugs is a syndicated market report, published as Global Super Generic Drugs Market Outlook 2021. It is complete Research Study and Industry Analysis of Super Generic Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $2,900.00
    $4,350.00
    $5,800.00
    2,120.36
    3,180.54
    4,240.72
    2,382.67
    3,574.00
    4,765.33
    301,008.40
    451,512.60
    602,016.80
    211,742.05
    317,613.08
    423,484.10
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report